Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 339Observational 58Expanded_access 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Neoplasms 11Multiple Myeloma 10Recurrence 9Pancreatic Neoplasms 8Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 6Neuroblastoma 6Melanoma 6Leukemia, Myeloid, Acute 6Sarcoma 5Hematologic Neoplasms 4Glioblastoma 4Breast Neoplasms 4Stomach Neoplasms 3Osteosarcoma 3Non-Muscle Invasive Bladder Neoplasms 3Neuroectodermal Tumors, Primitive 3Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2

Interventions

TIC10 compound 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Glioma × 1 year × Clear all
NCT04617002 2025-08-20

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Jazz Pharmaceuticals

Approved for marketing
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡